Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2023) 142 (Supplement 1): 6497.

https://doi.org/10.1182/blood-2023-186085

Published: 2023

Journal Articles

Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Blood (2023) 142 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2023-190091

Published: 2023

Journal Articles

Patients' Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform

Blood (2023) 142 (Supplement 1): 3714.

https://doi.org/10.1182/blood-2023-180574

Published: 2023

Journal Articles

Clinical Characteristics at Onset and Treatment Approaches in Young and Elderly Patients with Essential Thrombocitemia (ET) in Lazio Region: Evaluation of Retrospective and Prospective Databases

Alessandro Andriani, Massimo Breccia, Emilia Scalzulli, Elisabetta Cerchiara, Atelda Romano, Annalisa Biagi, Luca Maurillo, Malgorzata Monika Trawinska, Katia Paciaroni, Michelina Santopietro, Sabrina Leonetti Crescenzi, Ada D'Addosio, Caterina Tatarelli, Elisabetta Abruzzese, Ambra Di Veroli, Elena Rossi, Roberto Latagliata, Marco Montanaro

Blood (2022) 140 (Supplement 1): 12211–12212.

https://doi.org/10.1182/blood-2022-167056

Published: 2022

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2022) 140 (Supplement 1): 6176–6178.

https://doi.org/10.1182/blood-2022-167334

Published: 2022

Journal Articles

Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events

Roberto Latagliata, Alessandro Andriani, Massimo Breccia, Ida Carmosino, Federico Vozella, Atelda Romano, Annalisa Biagi, Luca Maurillo, Malgorzata Monika Trawinska, Katia Paciaroni, Michelina Santopietro, Sabrina Leonetti Crescenzi, Ada D'Addosio, Caterina Tatarelli, Elisabetta Abruzzese, Ambra Di Veroli, Elena Rossi, Valerio De Stefano, Marco Montanaro

Blood (2022) 140 (Supplement 1): 9691–9692.

https://doi.org/10.1182/blood-2022-165356

Published: 2022

Journal Articles

Clinical Utility and Physician Perceptions of a Digital Platform for Electronic Patient-Reported Outcomes Monitoring in Patients with Hematologic Malignancies in Real-World Practice

Blood (2021) 138 (Supplement 1): 4017.

https://doi.org/10.1182/blood-2021-146508

Published: 2021

Journal Articles

Specific Guidelines Including Multidisciplinary Approach Is Critical of Management of Langerhans Cell Histiocytosis in Adults

Lorenzo Rizzo, Michelina Santopietro, MD, Gianluca Sfaciotti, MD, Marco Brunori, MD, Luisa Cardarelli, MD, Giovanna Palumbo, MD, Daniela De Benedittis, MD, Martina Di Palma, Maria Luisa Moleti, MD, Anna Maria Testi, MD, Tiziana Di Pippo, Fiorina Giona, MD

Blood (2019) 134 (Supplement_1): 1041.

https://doi.org/10.1182/blood-2019-129707

Published: 2019

Journal Articles

Intermittent Imatinib Mesylate in Children with Chronic Myeloid Leukemia: Results and Outcome

Francesco Malaspina, MD, Maria Caterina Putti, MD, Michelina Santopietro, MD, Saverio Ladogana, MD, Rosamaria Mura, MD, Roberta Burnelli, MD, Nadia Vacca, MD, Lorenzo Rizzo, Maria Luisa Moleti, MD, Anna Maria Testi, MD, Andrea Biondi, Franco Locatelli, Giuseppe Saglio, Robin Foà, MD, Fiorina Giona, MD

Blood (2018) 132 (Supplement 1): 4256.

https://doi.org/10.1182/blood-2018-99-118030

Published: 2018

Journal Articles

Next-Generation Sequencing (NGS) in Childhood Myeloproliferative Diseases (MPD)

Michelina Santopietro, MD, Giovanna Palumbo, MD, Maria Luisa Moleti, MD, Anna Maria Testi, MD, Luisa Cardarelli, MD, Nicola Monaco, MDcal Student, Francesco Malaspina, MD, Camilla Presicce, MDcal Student, Sonia Maria Orlando, Alessandro Pancrazzi, PhD, Annalisa Pacilli, PhD, Giada Rotunno, PhD, Alessandro M. Vannucchi, MD, Robin Foà, MD, Fiorina Giona, MD

Blood (2018) 132 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2018-99-118102

Published: 2018

Journal Articles

Long-Term Outcome in Children and Adolescents with Chronic Myeloid Leukemia in Chronic Phase Treated with High-Dose Imatinib— the Italian Experience

Blood (2017) 130 (Supplement 1): 1600.

https://doi.org/10.1182/blood.V130.Suppl_1.1600.1600

Published: 2017

Journal Articles

Management of Chronic Myeloid Leukemia in Children and Adolescents According to Local Guidelines.the Italian Experience

Blood (2016) 128 (22): 3083.

https://doi.org/10.1182/blood.V128.22.3083.3083

Published: 2016

Journal Articles

Early Response Does Not Impact on the Long-Term Outcome of Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. the Italian Experience

Blood (2015) 126 (23): 2788.

https://doi.org/10.1182/blood.V126.23.2788.2788

Published: 2015

Journal Articles

Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a “Real-life” Patient Population With Chronic Myelogenous Leukemia?

Roberto Latagliata, MD, Ida Carmosino, Federico Vozella, Paola Volpicelli, MD, Giuseppina Loglisci, Michelina Santopietro, Adriano Salaroli, MD, Angela Romano, Chiara Montagna, Amanda Roberto, Alessandra Serrao, Daniela Diverio, PhD, Mauro Nanni, PhD, Marco Mancini, Agostino Tafuri, Massimo Breccia, Giuliana Alimena, MD

Blood (2013) 122 (21): 4002.

https://doi.org/10.1182/blood.V122.21.4002.4002

Published: 2013

Journal Articles

Clinical Relevance of an Extended Diagnostic Work-Out in Patients with Primary Autoimmune Amolytic Anemia (AIHA)

Francesca R Mauro, MD, PhD, Daniele Armiento, MD, Serelina Coluzzi, MD, Maria S De Propris, PhD, Francesca Paoloni, BS, Gianluca Giovannetti, MD, Matteo Molica, MD, Luisa Quattrocchi, MD, Michelina Santopietro, MD, Chiara Spadafora, Lucia Granati, MD, Mara Riminucci, MD, Anna Guarini, PhD, Gabriella Girelli, MD, Robin Foà, MD

Blood (2012) 120 (21): 3192.

https://doi.org/10.1182/blood.V120.21.3192.3192

Published: 2012

Journal Articles

Role of PET/CT in the Diagnostic Work-up of Patients with Chronic Lymphocytic Leukemia (CLL) and Clinical Signs of Disease Progression

Francesca R Mauro, MD, PhD, Mara Riminucci, MD, Davide Rossi, MD, PhD, Francesca Paoloni, BS, Luca Laurenti, MD, Anna M Frustaci, MD, Giuseppe Cimino, MD, Michelina Santopietro, MD, Chiara Spadafora, Angela Rago, M.D., Francesco Autore, MD, Molica Matteo, MD, Brocchieri Simonetta, MD, Emanuele Nicolai, MD, Gianluca Gaidano, MD, PhD, Anna Guarini, PhD, Bianco Paolo, MD, Robin Foà, MD

Blood (2012) 120 (21): 3888.

https://doi.org/10.1182/blood.V120.21.3888.3888

Published: 2012

Journal Articles

Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib

Paola Volpicelli, MD, Roberto Latagliata, MD, Massimo Breccia, Federico Vozella, Paola Finsinger, Ida Carmosino, Giuseppina Loglisci, MD, Michelina Santopietro, MD, Adriano Salaroli, Daniela Diverio, PhD, Marco Mancini, MD, Agostino Tafuri, Giuliana Alimena

Blood (2012) 120 (21): 3769.

https://doi.org/10.1182/blood.V120.21.3769.3769

Published: 2012

Journal Articles

Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,

Roberto Latagliata, Massimo Breccia, Ida Carmosino, Federico Vozella, Paola Volpicelli, Antonietta Ferretti, Giuseppina Loglisci, MD, Michelina Santopietro, Vincenzo Federico, Rosa De Cuia, Daniela Diverio, Mauro Nanni, PhD, Marco Mancini, Giuliana Alimena

Blood (2011) 118 (21): 3783.

https://doi.org/10.1182/blood.V118.21.3783.3783

Published: 2011

Journal Articles

MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients,

Massimo Breccia, Vincenzo Federico, Giuseppina Loglisci, Roberto Latagliata, Michelina Santopietro, Adriano Salaroli, Alessandra Serrao, Gioia Colafigli, Agostino Tafuri, Giuliana Alimena

Blood (2011) 118 (21): 3793.

https://doi.org/10.1182/blood.V118.21.3793.3793

Published: 2011

Journal Articles

Hammersmith Score Is Able to Identify Chronic Myeloid Leukemia Patients with Poor Prognosis Before Treatment with Second-Generation TKIs.

Massimo Breccia, Roberto Latagliata, MD, Fabio Stagno, Antonella Gozzini, Elisabetta Abruzzese, Antonella Russo Rossi, Michelina Santopietro, Laura Cannella, Federica Sorà, Paolo Vigneri, Malgorzata Trawinska, Simona Sica, Giorgina Specchia, Valeria Santini, MD, Giuliana Alimena

Blood (2010) 116 (21): 3409.

https://doi.org/10.1182/blood.V116.21.3409.3409

Published: 2010

NARROW

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Patients' Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform

Clinical Characteristics at Onset and Treatment Approaches in Young and Elderly Patients with Essential Thrombocitemia (ET) in Lazio Region: Evaluation of Retrospective and Prospective Databases

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events

Clinical Utility and Physician Perceptions of a Digital Platform for Electronic Patient-Reported Outcomes Monitoring in Patients with Hematologic Malignancies in Real-World Practice

Specific Guidelines Including Multidisciplinary Approach Is Critical of Management of Langerhans Cell Histiocytosis in Adults

Intermittent Imatinib Mesylate in Children with Chronic Myeloid Leukemia: Results and Outcome

Next-Generation Sequencing (NGS) in Childhood Myeloproliferative Diseases (MPD)

Long-Term Outcome in Children and Adolescents with Chronic Myeloid Leukemia in Chronic Phase Treated with High-Dose Imatinib— the Italian Experience

Management of Chronic Myeloid Leukemia in Children and Adolescents According to Local Guidelines.the Italian Experience

Early Response Does Not Impact on the Long-Term Outcome of Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. the Italian Experience

Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a “Real-life” Patient Population With Chronic Myelogenous Leukemia?

Clinical Relevance of an Extended Diagnostic Work-Out in Patients with Primary Autoimmune Amolytic Anemia (AIHA)

Role of PET/CT in the Diagnostic Work-up of Patients with Chronic Lymphocytic Leukemia (CLL) and Clinical Signs of Disease Progression

Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib

Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,

MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients,

Hammersmith Score Is Able to Identify Chronic Myeloid Leukemia Patients with Poor Prognosis Before Treatment with Second-Generation TKIs.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only